The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Production of α2,6-sialylated IgG1 in CHO cells
Open accessAbstract
The presence of α2,6-sialic acids on the Fc N-glycan provides anti-inflammatory properties to the IgGs through a mechanism that remains unclear. Fc-sialylated IgGs are rare in humans as well as in industrial host cell lines such as Chinese hamster ovary (CHO) cells. Facilitated access to well-characterized α2,6-sialylated IgGs would help elucidate the mechanism of this intriguing IgG's effector function. This study presents a method for the efficient Fc glycan α2,6-sialylation of a wild-type and a F243A IgG1 mutant by transient co-expression with the human α2,6-sialyltransferase 1 (ST6) and β1,4-galactosyltransferase 1 (GT) in CHO cells. Overexpression of ST6 alone only had a moderate effect on the glycoprofiles, whereas GT alone greatly enhanced Fc-galactosylation, but not sialylation. Overexpression of both GT and ST6 was necessary to obtain a glycoprofile dominated by α2,6-sialylated glycans in both antibodies. The wild-type was composed of the G2FS(6)1 glycan (38%) with remaining unsialylated glycans, while the mutant glycoprofile was essentially composed of G2FS(6)1 (25%), G2FS(3,6)2 (16%) and G2FS(6,6)2 (37%). The α2,6-linked sialic acids represented over 85% of all sialic acids in both antibodies. We discuss how the limited sialylation level in the wild-type IgG1 expressed alone or with GT results from the glycan interaction with Fc's amino acid residues or from intrinsic galactosyl- and sialyl-transferases substrate specificities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Co-expression of ST6Gal1 and β4GalT1 in CHO cells also significantly enhanced the sialylation level of the mutated version of trastuzumab (Raymond et al., 2015).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Raymond et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,354
Durocher, Y. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.2.e9 · Cited by 1,037
Self-citationRecapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature reviews. Immunology · doi:10.1038/nri2761 · Cited by 846
Bigge, J. C., Patel, T. P., Bruce, J., Goulding, P. N., Charles, S., & Parekh, R. B. (1995) · Analytical Biochemistry · doi:10.1006/abio.1995.1468 · Cited by 825
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 690
The human sialyltransferase family
Harduin‐Lepers, A., Vallejo‐Ruiz, V., Krzewinski‐Recchi, M., Samyn-Petit, B., Julien, S., & Delannoy, P. (2001) · Biochimie · doi:10.1016/s0300-9084(01)01301-3 · Cited by 580
Research works printed but not linked: 4
- Scott AM, 2012, Cancer Immun, 12, 14
- Ferrara C, 2006, Biotechnol Appl Biochem, 93, 851
- 10.1111/j.1537-2995.2011.03517 · DOI
- Royle L, 2006, Methods Mol Biol, 347, 125
Cited by
Sorted by citations
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296
Self-citationGlycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 266
Mimura, Y., Katoh, T., Saldova, R., O’Flaherty, R., Izumi, T., Mimura‐Kimura, Y., Utsunomiya, T., Mizukami, Y., Yamamoto, K., Matsumoto, T., et al. (2017) · Protein & Cell · doi:10.1007/s13238-017-0433-3 · Cited by 221
Prediction and Reduction of the Aggregation of Monoclonal Antibodies
van der Kant, R., Karow‐Zwick, A. R., Durme, J. V., Blech, M., Gallardo, R. U., Seeliger, D., Aßfalg, K., Baatsen, P., Compernolle, G., Gils, A., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.014 · Cited by 149
Glycoengineering of Antibodies for Modulating Functions
Wang, L., Tong, X., Li, C., Giddens, J. P., & Li, T. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-012911 · Cited by 140
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans
Dekkers, G., Plomp, R., Koeleman, C. A. M., Visser, R., von Horsten, H. H., Sandig, V., Rispens, T., Wuhrer, M., & Vidarsson, G. (2016) · Scientific Reports · doi:10.1038/srep36964 · Cited by 123
Sjögren, J., Olsson, F., & Beck, A. (2016) · The Analyst · doi:10.1039/c6an00071a · Cited by 106
Gahoual, R., Beck, A., Leize‐Wagner, E., & François, Y. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.05.028 · Cited by 111
Impact of cell culture media additives on IgG glycosylation produced in Chinese hamster ovary cells
Ehret, J., Zimmermann, M., Eichhorn, T., & Zimmer, A. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26904 · Cited by 104
Sialylation as an Important Regulator of Antibody Function
Vattepu, R., Sneed, S. L., & Anthony, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818736 · Cited by 104
Antibody glycoengineering strategies in mammalian cells
Wang, Q., Chung, C., Chough, S., & Betenbaugh, M. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26567 · Cited by 95
Protein Glycoengineering: An Approach for Improving Protein Properties
Ma, B., Guan, X., Li, Y., Shang, S., Li, J., & Tan, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00622 · Cited by 86
Largy, E., Cantais, F., Vyncht, G. V., Beck, A., & Delobel, A. (2017) · Journal of Chromatography A · doi:10.1016/j.chroma.2017.02.072 · Cited by 79
Small-molecule control of antibody N-glycosylation in engineered mammalian cells
Chang, M. M., Gaidukov, L., Jung, G., Tseng, W. A., Scarcelli, J. J., Cornell, R. J., Marshall, J. K., Lyles, J. L., Sakorafas, P., Chu, A. A., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0288-4 · Cited by 73
Glycoengineering in CHO cells: advances in systems biology
Tejwani, V., Andersen, M. R., Nam, J. H., & Sharfstein, S. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700234 · Cited by 70
Majewska, N. I., Tejada, M. L., Betenbaugh, M. J., & Agarwal, N. (2020) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-102419-010001 · Cited by 72
Customized protein glycosylation to improve biopharmaceutical function and targeting
Van Landuyt, L., Lonigro, C., Meuris, L., & Callewaert, N. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.11.017 · Cited by 66
Improving Immunotherapy Through Glycodesign
Buettner, M. J., Shah, S. R., Saeui, C. T., Ariss, R., & Yarema, K. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02485 · Cited by 68
Stuible, M., Burlacu, A., Perret, S., Brochu, D., Paul‐Roc, B., Baardsnes, J., Loignon, M., Grazzini, E., & Durocher, Y. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.06.307 · Cited by 49
Self-citationChung, C., Wang, Q., Yang, S., Yin, B., Zhang, H., & Betenbaugh, M. J. (2016) · Biotechnology Journal · doi:10.1002/biot.201600502 · Cited by 50
Zhong, X., Ma, W., Meade, C., Tam, A. S. P., Llewellyn, E., Cornell, R. J., Cote, K., Scarcelli, J. J., Marshall, J. K., Tzvetkova, B., et al. (2018) · Biotechnology Progress · doi:10.1002/btpr.2724 · Cited by 47
Impact of Fc N-glycan sialylation on IgG structure
Zhang, Z., Shah, B., & Richardson, J. (2019) · mAbs · doi:10.1080/19420862.2019.1655377 · Cited by 46
Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases
Li, D., Lou, Y., Zhang, Y., Liu, S., Li, J., & Tao, J. (2021) · Theranostics · doi:10.7150/thno.53961 · Cited by 46
Chia, S., Tay, S. J., Song, Z., Yang, Y., Walsh, I., & Pang, K. T. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114757 · Cited by 46
Li, H., Gao, W., Feng, X., Liu, B., & Liu, X. (2016) · Analytica Chimica Acta · doi:10.1016/j.aca.2016.04.023 · Cited by 44
Höti, N., Yang, S., Hu, Y., Shah, P., Haffner, M. C., & Zhang, H. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-017-0016-7 · Cited by 44
Modulating antibody effector functions by Fc glycoengineering
García-Alija, M., Moer, B. V., Sastre, D. E., Azzam, T., Du, J. J., Trastoy, B., Callewaert, N., Sundberg, E. J., & Guerin, M. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108201 · Cited by 43
On the Use of Surface Plasmon Resonance Biosensing to Understand IgG-FcγR Interactions
Forest‐Nault, C., Gaudreault, J., Henry, O., Durocher, Y., & Crescenzo, G. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126616 · Cited by 43
Self-citationGlycoengineering design options for IgG1 in CHO cells using precise gene editing
Schulz, M. A., Tian, W., Mao, Y., Coillie, J. V., Sun, L., Larsen, J. S., Chen, Y., Kristensen, C., Vakhrushev, S. Y., Clausen, H., et al. (2018) · Glycobiology · doi:10.1093/glycob/cwy022 · Cited by 41
Glycoengineering Chinese hamster ovary cells: a short history
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37
Nguyen, N., Lin, J., Tay, S. J., Mariati, Yeo, J. H. M., Nguyen‐Khuong, T., & Yang, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-92320-x · Cited by 38
Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines
Mimura, Y., Kelly, R. M., Unwin, L., Albrecht, S., Jefferis, R., Goodall, M. D., Mizukami, Y., Mimura‐Kimura, Y., Matsumoto, T., Ueoka, H., et al. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.11.009 · Cited by 35
Höti, N., Lih, T. M., Pan, J., Zhou, Y., Yang, G., Deng, A., Chen, L., Dong, M., Yang, R., Tu, C.-F., et al. (2020) · Cancers · doi:10.3390/cancers12020468 · Cited by 35
Cagnoni, A. J., Troncoso, M. F., Rabinovich, G. A., Mariño, K. V., & Elola, M. T. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200311 · Cited by 31
Cell factory engineering: Challenges and opportunities for synthetic biology applications
Bachhav, B., de Rossi, J., Llanos, C. P., & Segatori, L. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28365 · Cited by 33
Rowley, T. F., Peters, S. J., Aylott, M. C., Griffin, R., Davies, N. L., Healy, L. J., Cutler, R. M., Eddleston, A., Pither, T. L., Sopp, J. M., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0149-9 · Cited by 29
Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
Li, S., McCraw, A. J., Gardner, R. A., Spencer, D. I. R., Karagiannis, S. N., & Wagner, G. K. (2021) · Antibodies · doi:10.3390/antib10040044 · Cited by 27
de Oliveira, A. G. G., Roy, R., Raymond, C., Bodnar, E. D., Tayi, V. S., Butler, M., Durocher, Y., & Perreault, H. (2015) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.7287 · Cited by 27
Self-citationmAbs N-glycosylation: Implications for biotechnology and analytics
Wang, T., Liu, L., & Voglmeir, J. (2022) · Carbohydrate Research · doi:10.1016/j.carres.2022.108541 · Cited by 25
Yu, C., Gao, K., Zhu, L., Wang, W., Wang, L., Zhang, F., Liu, C., Li, M., Wormald, M. R., Rudd, P. M., et al. (2016) · Scientific Reports · doi:10.1038/srep20029 · Cited by 26
Cambay, F., Henry, O., Durocher, Y., & Crescenzo, G. D. (2019) · mAbs · doi:10.1080/19420862.2019.1581017 · Cited by 29
Self-citationImpact of IgG1 N-glycosylation on their interaction with Fc gamma receptors
Cambay, F., Raymond, C., Brochu, D., Gilbert, M., Tu, T.-M., Cantin, C., Lenferink, A. E. G., Grail, M., Henry, O., Crescenzo, G. D., et al. (2020) · Current Research in Immunology · doi:10.1016/j.crimmu.2020.06.001 · Cited by 24
Self-citationSolid‐Phase Enzymatic Remodeling Produces High Yields of Single Glycoform Antibodies
Tayi, V. S., & Butler, M. (2017) · Biotechnology Journal · doi:10.1002/biot.201700381 · Cited by 18
Self-citationLarge-scale quantitative isolation of pure protein N-linked glycans
Valk‐Weeber, R. L., Dijkhuizen, L., & van Leeuwen, S. S. (2019) · Carbohydrate Research · doi:10.1016/j.carres.2019.04.011 · Cited by 21
Recombinant Proteins and Monoclonal Antibodies
Jefferis, R. (2017) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2017_32 · Cited by 21
Liu, R., Giddens, J. P., McClung, C. M., Magnelli, P. E., Wang, L., & Guthrie, E. P. (2015) · mAbs · doi:10.1080/19420862.2015.1113361 · Cited by 20
Wang, Q., Wang, T., Zhang, R., Yang, S., McFarland, K. S., Chung, C., Jia, H., Wang, L., Cipollo, J. F., & Betenbaugh, M. J. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27953 · Cited by 22
Bigelow, E., Song, Y., Chen, J., Holstein, M. A., Huang, Y., Duhamel, L., Stone, K., Furman, R., Li, Z. J., & Ghose, S. (2021) · Journal of Chromatography A · doi:10.1016/j.chroma.2021.462008 · Cited by 19
Sun, T., Kwok, W. C., Chua, K. J., Lo, T., Potter, J., Yew, W. S., Chesnut, J. D., Hwang, I. Y., & Chang, M. W. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00221 · Cited by 18
Gupta, R., Ponangi, R., & Indresh, K. G. (2023) · Glycobiology · doi:10.1093/glycob/cwad046 · Cited by 18
Watson, D. C., Wakarchuk, W. W., Gervais, C., Durocher, Y., Robotham, A. C., Fernandes, S. M., Schnaar, R. L., Young, N. M., & Gilbert, M. (2015) · Glycoconjugate Journal · doi:10.1007/s10719-015-9624-4 · Cited by 18
Self-citationVector-related stratagems for enhanced monoclonal antibody production in mammalian cells
Gupta, K., Parasnis, M. S., Jain, R. D., & Dandekar, P. P. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107415 · Cited by 17
Sneed, S. L., Reese, B. B., Laureano, A. F. S., Ratnapriya, S., Fraschilla, I. R., Jeffrey, K. L., Coffey, G., Conley, P. B., & Anthony, R. M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci172980 · Cited by 16
Altering the central carbon metabolism of HEK293 cells: Impact on recombinant glycoprotein quality
Karengera, E., Robotham, A. C., Kelly, J. F., Durocher, Y., Crescenzo, G. D., & Henry, O. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.12.003 · Cited by 16
Self-citationA glyco-engineering approach for site-specific conjugation to Fab glycans
Jaramillo, M., Sulea, T. I., Durocher, Y., Acchione, M., Schur, M. J., Robotham, A. C., Kelly, J. F., Goneau, M.-F., Robert, A., Donates, Y. C., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2149057 · Cited by 15
Self-citationPark, C. S., Kang, M., Kim, A.-H., Moon, C., Kim, M., Kim, J., Yang, S., Jang, L., Jang, J. Y., & Kim, H. H. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.01.001 · Cited by 15
Inhibition of glycosylation on a camelid antibody uniquely affects its FcγRI binding activity
Krahn, N., Spearman, M. A., Meier, M., Dorion-Thibaudeau, J., McDougall, M., Patel, T. R., Crescenzo, G. D., Durocher, Y., Stetefeld, J., & Butler, M. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.09.040 · Cited by 14
Self-citationPark, J. S., Choi, H. J., Jung, K. M., Lee, K. Y., Shim, J. H., Park, K. J., Kim, Y., & Han, J. Y. (2023) · Communications Biology · doi:10.1038/s42003-023-04937-5 · Cited by 13
Production of α2,6-sialylated and non-fucosylated recombinant alpha-1-antitrypsin in CHO cells
Lalonde, M., Koyuturk, I., Brochu, D., Jabbour, J., Gilbert, M., & Durocher, Y. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.10.021 · Cited by 13
Self-citationMartina, M., Banderali, U., Yogi, Á., Ghahroudi, M. A., Liu, H. S., Sulea, T. I., Durocher, Y., Hussack, G., van Faassen, H., Chakravarty, B., et al. (2024) · Advanced Science · doi:10.1002/advs.202405432 · Cited by 12
Self-citationThe anti-inflammatory activity of IgG is enhanced by co-engagement of type I and II Fc receptors
Jones, A., Marino, A. E., Martynyuk, T., Bournazos, S., & Ravetch, J. V. (2025) · Science · doi:10.1126/science.adv2927 · Cited by 11
Cell engineering for the production of hybrid-type N-glycans in HEK293 cells
Leng, J.-X., Ren, W., Li, Y., Yang, G., Gao, X., & Fujita, M. (2021) · The Journal of Biochemistry · doi:10.1093/jb/mvab051 · Cited by 11
Hélie, G., Parat, M., Massé, F., Gerdts, C. J., Loisel, T. P., & Matte, A. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.06.001 · Cited by 10
de Oliveira, K. B., Spencer, D., Barton, C., & Agarwal, N. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26266 · Cited by 10
Developability Assessment of a Proposed NIST Monoclonal Antibody
Saro, D., Baker, A. E., Hepler, R. W., Spencer, S., Bruce, R., LaBrenz, S. R., Chiu, M. L., Davis, D., & Lang, S. E. (2015) · ACS symposium series · doi:10.1021/bk-2015-1201.ch007 · Cited by 10
Karengera, E., Durocher, Y., Crescenzo, G. D., & Henry, O. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-017-8513-0 · Cited by 10
Self-citationCHO Cell Engineering for Improved Process Performance and Product Quality
Fischer, S., & Otte, K. (2019) · doi:10.1002/9783527811410.ch9 · Cited by 9
Bodnar, E. D., Raymond, C., Lopez, P. G., Villacrés, C., Butler, M., Schoenhofen, I. C., Durocher, Y., & Perreault, H. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-9010-x · Cited by 8
Self-citationLim, J.-H., Kim, J., Cha, H.-M., Kang, S.-H., Han, H., Ji, M., Cheon, S., Kang, M., Kim, H. H., & Kim, D. (2022) · Enzyme and Microbial Technology · doi:10.1016/j.enzmictec.2022.110007 · Cited by 8
Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics
Mastrangeli, R., Satwekar, A., & Bierau, H. (2023) · Molecules · doi:10.3390/molecules28083304 · Cited by 7
Metabolic engineering of CHO cells to prepare glycoproteins
Wang, Q., & Betenbaugh, M. J. (2018) · Emerging Topics in Life Sciences · doi:10.1042/etls20180056 · Cited by 7
Application of Genetic Engineering in Biotherapeutics Development
Schweickert, P. G., & Cheng, Z. (2019) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-019-09411-6 · Cited by 8
Glycoproteomics Technologies in Glycobiotechnology
Alagesan, K., Hoffmann, M., Rapp, E., & Kolarich, D. (2020) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2020_144 · Cited by 6
Producing Biologics with Defined N-Glycosylation in Plants
Esqueda, A., & Chen, Q. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2835-5_17 · Cited by 6
Baniahmad, S. F., Oliverio, R., Obregon-Gomez, I., Robert, A., Lenferink, A. E. G., Pazos, E., Virgilio, N., Banquy, X., Crescenzo, G. D., & Durocher, Y. (2023) · mAbs · doi:10.1080/19420862.2023.2218951 · Cited by 6
Self-citationNguyen, N. T. B., Leung, H. W., Pang, K. T., Tay, S. J., Walsh, I., Choo, A. B. H., & Yang, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-42925-1 · Cited by 5
Wang, S., Tian, H., Tian, P., Xing, Y., & Zeng, Y. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1371 · Cited by 6
AlbuCORE: an albumin-based molecular scaffold for multivalent biologics design
Sanches, M., D’Angelo, I., Jaramillo, M., Baardsnes, J., Zwaagstra, J. C., Schrag, J., Schoenhofen, I. C., Acchione, M., Lawn, S. O., Wickman, G., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1802188 · Cited by 5
Schlossbauer, P., Naumann, L., Klingler, F., Burkhart, M., Handrick, R., Korff, K., Neusüß, C., Otte, K., & Hesse, F. (2024) · Engineering in Life Sciences · doi:10.1002/elsc.202300234 · Cited by 4
Rapid Antibody Glycoengineering in CHO Cells Via RNA Interference and CGE-LIF N-Glycomics
Kotidis, P., Marbiah, M. M., Donini, R., Gómez, I. A., del Val, I. J., Haslam, S. M., Polizzi, K. M., & Kontoravdi, C. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1685-7_7 · Cited by 3
La bioproduction des anticorps monoclonaux
Joubert, S., Dodelet, V. C., Béliard, R., & Durocher, Y. (2019) · médecine/sciences · doi:10.1051/medsci/2019219 · Cited by 6
Self-citationDonald, L. J., Spearman, M. A., Mishra, N., Komatsu, E., Butler, M., & Perreault, H. (2020) · Molecular Omics · doi:10.1039/c9mo00168a · Cited by 4
Self-citationMetayer, I., Forest‐Nault, C., Guimond, J., Joubert, S., Henry, O., Durocher, Y., Crescenzo, G. D., & Gaudreault, J. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.70016 · Cited by 3
Self-citationUse of Coiled-Coil Affinity Peptides to Manufacture Antibody Conjugates
Baniahmad, S. F., Burlacu, A., Delafosse, L., Acchione, M., Simmons, M., Ling, B., Iqbal, U. H., Moreno, M., Crescenzo, G. D., & Durocher, Y. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00178 · Cited by 3
Self-citationAlkanaimsh, S., AlSalal, A. M., & El-Touney, H. (2024) · Processes · doi:10.3390/pr12050979 · Cited by 3
Zhong, J., Huang, M., Qiu, H., Seol, H., Yan, Y., Wang, S., & Li, N. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.11.024 · Cited by 3
Production of IgGs with a human-like sialylation in CHO cells
Raymond, C., Robotham, A. C., Spearman, M. A., Butler, M., Kelly, J. F., & Durocher, Y. (2015) · BMC Proceedings · doi:10.1186/1753-6561-9-s9-o3 · Cited by 3
Self-citationOne‐step production of fully biotinylated and glycosylated human Fc gamma receptors
Kang, M., Wang, Z., & Ge, X. (2023) · Biotechnology Progress · doi:10.1002/btpr.3392 · Cited by 3
Pranomphon, R., Tejwani, V., Dahodwala, H., Yamabhai, M., & Sharfstein, S. T. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_6 · Cited by 2
Animal Cell Expression Systems
Butler, M., & Reichl, U. (2017) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2017_31 · Cited by 2
Self-citationLim, J.-H., Cha, H.-M., Park, H., Kim, H. H., & Kim, D. (2017) · KSBB Journal · doi:10.7841/ksbbj.2017.32.3.193 · Cited by 2
The anti-inflammatory activity of IgG requires the co-engagement of types I and II Fc receptorsPreprint
Jones, A., Martynyuk, T., Marino, A. E., Bournazos, S., & Ravetch, J. V. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.16.628704 · Cited by 2
Expression Systems for Recombinant Biopharmaceutical Production by Mammalian Cells in Culture
Brown, A. J., Kalsi, D., Fernandez‐Martell, A., Cartwright, J., Barber, N., Patel, Y. D., Turner, R., Bryant, C. L., Johari, Y. B., & James, D. C. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch13 · Cited by 1
Spearman, M. A., Lattová, E., Perreault, H., & Butler, M. (2018) · Wiley eBooks · doi:10.1002/9781119378341.ch3
Self-citationMonoclonal Antibody Glycoengineering for Biopharmaceutical Quality Assurance
Gómez, I. A., & del Val, I. J. (2021) · Cell engineering · doi:10.1007/978-3-030-79871-0_6
Schlossbauer, P., Klingler, F., & Hesse, F. (2024) · Re GEN Open · doi:10.1089/regen.2023.0027
Schlossbauer, P., Klingler, F., Burkhart, M., Leroux, A., Hesse, F., & Otte, K. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4104-0_7 · Cited by 1
Zhao, B., Zhang, B., Kang, Y., Liu, S., Jia, Z., Lu, C., Cao, Y., Xu, A., Lee, K., Zhang, Z., et al. (2025) · Biotechnology Progress · doi:10.1002/btpr.70091
Genetic Factors Affecting the Quality of Recombinant Therapeutic Proteins in CHO Cells
Mi, C., Geng, S., Xue, J., Sun, Q.-L., Dong, W.-H., Zhang, J., Li, Q., Wang, X.-Y., & Wang, T.-Y. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c01454
Integrating text mining and knowledge graph to enhance biopharmaceutical process optimization
Bhowmik, S., Anandakrishnan, M., Klein, L., Arighi, C., Gioioso, M., Wu, C., Brockmeier, A. J., Vijay-Shanker, K., & Chen, C.-M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0339197
Metadata
- Authors
- Raymond, C., Robotham, A., Spearman, M., Butler, M., Kelly, J., & Durocher, Y.
- Affiliations
- National Research Council Canada (CA)
- University of Manitoba (CA)
- Corresponding author
- Durocher, Yves
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2015-04-15
- Volume
- 7
- Issue
- 3
- Pages
- 571-583
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- PMC
- PMC4622614
- OpenAlex
- W1592578892
- Cited by
- 106
- References
- 65
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 10 · 2023: 10 · 2022: 6 · 2021: 10 · 2020: 9 · 2019: 11 · 2018: 12 · 2017: 11 · 2016: 9 · 2015: 7
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- mAbs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- NPARC (submittedVersion)
- Funders
- Natural Sciences and Engineering Research Council of Canada
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- α2,6-sialylation, IgG1, Fc glycan, sialic acid, beta-1,4-galactosyltransferase, CHO cells, antibody glycosylation
- MeSH terms
- beta-D-Galactoside alpha 2-6-Sialyltransferase, Animals, Antibodies, Monoclonal, Cricetulus, Cricetinae, Humans, Immunoglobulin G, N-Acetyllactosamine Synthase, Sialic Acids, Sialyltransferases, Antigens, CD, CHO Cells, Amino Acid Substitution, Mutation, Missense
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review